1,627 matches
-
și microbicide anti-HIV) împotriva bolilor vizate, prin finanțarea gamei complete de activități de cercetare, de la cercetare moleculară de bază, valorificând avantajul oferit de genomica microbiană, până la testarea preclinică și demonstrarea principiilor; instituirea unui program în vederea unirii și susținerii activităților de trial clinic la nivel european care urmăresc în mod special intervențiile care vor fi aplicate în țările în curs de dezvoltare; instituirea unei rețele europene de trialuri pentru terapia anti-SIDA care să îmbunătățească coerența și complementaritatea trialurilor clinice ale terapiilor anti-SIDA
jrc5559as2002 by Guvernul României () [Corola-website/Law/90729_a_91516]
-
testarea preclinică și demonstrarea principiilor; instituirea unui program în vederea unirii și susținerii activităților de trial clinic la nivel european care urmăresc în mod special intervențiile care vor fi aplicate în țările în curs de dezvoltare; instituirea unei rețele europene de trialuri pentru terapia anti-SIDA care să îmbunătățească coerența și complementaritatea trialurilor clinice ale terapiilor anti-SIDA utilizate la nivel european. Activitățile de cercetare desfășurate în cadrul acestui domeniu tematic prioritar vor cuprinde activități de explorare la nivelul de vârf al cunoștințelor cu privire la subiecte
jrc5559as2002 by Guvernul României () [Corola-website/Law/90729_a_91516]
-
și susținerii activităților de trial clinic la nivel european care urmăresc în mod special intervențiile care vor fi aplicate în țările în curs de dezvoltare; instituirea unei rețele europene de trialuri pentru terapia anti-SIDA care să îmbunătățească coerența și complementaritatea trialurilor clinice ale terapiilor anti-SIDA utilizate la nivel european. Activitățile de cercetare desfășurate în cadrul acestui domeniu tematic prioritar vor cuprinde activități de explorare la nivelul de vârf al cunoștințelor cu privire la subiecte care sunt strâns legate de unul sau mai multe subiecte
jrc5559as2002 by Guvernul României () [Corola-website/Law/90729_a_91516]
-
în curs de dezvoltare; îngrijirea paliativă; activitățile vizate vor fi puse în aplicare, de exemplu, prin coordonarea studiilor de cercetare și comparative, prin dezvoltarea bazelor de date europene și a rețelelor interdisciplinare, prin schimbul de practici clinice și prin coordonarea trialurilor clinice. - biotehnologia: aplicații care nu sunt legate de sănătate sau de alimentație; - mediul: mediul urban (inclusiv dezvoltarea urbană durabilă și patrimoniul cultural, inclusiv, de exemplu, conceptul de "ecosituri"); mediul maritim și gestionarea terenurilor/ a solului; riscul seismic. - energia: centrale electrice
jrc5559as2002 by Guvernul României () [Corola-website/Law/90729_a_91516]
-
P, Santandrea, S, Boccassini, L, et al. The role of NSAIDs în psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001; 19:S17. 14. Willkens, RF, Williams, HJ, Ward, JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate în psoriatic arthritis. Arthritis Rheum 1984; 27:376. 15. Abu-Shakra, M, Gladman, DD, Thorne, JC, et al. Long-term methotrexate therapy în psoriatic arthritis: Clinical and radiologic outcome. J Rheumatol 1995; 22:241. 16. Soriano, ER, McHugh
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
et al. Leflunomide în psoriatic polyarthritis. J Clin Rheumatol 2002; 8:286. 24. Kaltwasser, JP, Nash, P, Gladman, D, et al. Efficacy and safety of leflunomide în the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50:1939. 25. Dougados, M, van der Linden, S, Leirisalo-Repo, M, et al. Sulfasalazine în the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38:618. 26. Gupta, AK, Grober JS, Hamilton, TA
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
Leirisalo-Repo, M, et al. Sulfasalazine în the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38:618. 26. Gupta, AK, Grober JS, Hamilton, TA, et al. Sulfasalazine therapy for psoriatic arthritis: A double blind, placebo controlled trial. J Rheumatol 1995; 22:894. 27. Clegg, DO, Reda, DJ, Abdellatif, M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a department of veterans affairs cooperative study. Arthritis Rheum 1999
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
Brautigam, M, et al. Anti-inflammatory efficacy of low-dose cyclosporin A în psoriatic arthritis. A prospective multicentre study. Br J Dermatol 1996; 135:752. 32. Fraser, AD, van Kuijk, AW, Westhovens, R, et al. A randomised, doubleblind, placebo controlled, mulți- centre trial of combination therapy with methotrexate plus cyclosporin în patients with active psoriatic arthritis. Ann Rheum Dis 2004. 33. Gladman, DD, Blake, R, Brubacher, B, Farewell, VT. Chloroquine therapy în psoriatic arthritis. J Rheumatol 1992; 19:1724. 34. Palit, J, Hill
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
inhibitors în the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008; 35:883. 40. Mease, PJ, Goffe, BS, Metz, J, et al. Etanercept în the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385. 41. Mease, PJ, Kivitz, AJ, Burch, FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50:2264. 42. Mease, PJ, Kivitz, AJ, Burch, FX, et al. Continued
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
psoriasis and psoriatic arthritis. Ann Rheum Dis 2004; 63:769. 48. Antoni, CE, Kavanaugh, A, Kirkham, B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52:1227. 49. Antoni, C, Krueger, GG, de Vlam, K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150. 50. Kavanaugh, A, Antoni
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52:1227. 49. Antoni, C, Krueger, GG, de Vlam, K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150. 50. Kavanaugh, A, Antoni, CE, Gladman, D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006; 65:1038. 51. Antoni, CE, Kavanaugh
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
de Vlam, K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150. 50. Kavanaugh, A, Antoni, CE, Gladman, D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006; 65:1038. 51. Antoni, CE, Kavanaugh, A, van der, HD, et al. Two-Year Efficacy and Safety of Infliximab Treatment în Patients with Active Psoriatic Arthritis: Findings of the
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
after 1 year. Ann Rheum Dis 2006; 65:1038. 51. Antoni, CE, Kavanaugh, A, van der, HD, et al. Two-Year Efficacy and Safety of Infliximab Treatment în Patients with Active Psoriatic Arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35:869. 52. Mease, PJ, Gladman, DD, Ritchlin, CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:3279
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35:869. 52. Mease, PJ, Gladman, DD, Ritchlin, CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:3279. 53. Gladman, DD, Mease, PJ, Ritchlin, CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness în psoriatic arthritis trial. Arthritis Rheum 2007; 56:476. 54. Genovese, MC
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:3279. 53. Gladman, DD, Mease, PJ, Ritchlin, CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness în psoriatic arthritis trial. Arthritis Rheum 2007; 56:476. 54. Genovese, MC, Mease, PJ, Thomson, GT, et al. Safety and efficacy of adalimumab în treatment of patients with psoriatic arthritis who had failed disease modifying antireumatic drug therapy. J Rheumatol 2007; 34:1040. 55
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
arthritis în patients treated with efalizumab for moderate to severe psoriasis. Arthritis Rheum 2008; 58:1796. 65. Gottlieb, A, Menter, A, Mendelsohn, A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633. 66. Gladman, DD, Helliwell, P, Mease, PJ, et al. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004; 50:24. 67. Gladman, DD, Mease, PJ, Strand, V, et al. Consensus
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
la 10 cazuri pentru granulomatoza Wegener. (37). Raritatea acestor boli, simptomatologia polimorfă, dificultatea de a diferenția manifestările bolii active de sechelele cicatriceale ireversibile, necesitatea unor proceduri investigaționale sau terapeutice specializate, decizia unui tratament agresiv ca și posibilitatea de înrolare în trialuri clinice a pacienților cu boala refractară, recomandă existența unor centre de expertiză specializate pentru îngrijirea acestor bolnavi. (nivel de dovezi 3, gradul de recomandare D) (35). Pacienții cu vasculită necesită urmărire pe termen lung, recurențele fiind oricând posibile ca și
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
angiographic classification. Scand J Rheumatol 2005;34:284-92. 7. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with highdose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006;54:3310-8. 8. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18. 9
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
cell arteritis using induction therapy with highdose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006;54:3310-8. 8. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18. 9. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18. 9. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621-30. 10. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, FernandezGutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-14. 11
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621-30. 10. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, FernandezGutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-14. 11. Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens în treatment of giant cell arteritis: comparison în a prospective study. Ann Intern Med 1975;82:613-8. 12. Danesh-Meyer H
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
HA, et al. ANCA are detectable în nearly all patients with active severe Wegener'sgranulomatosis. Am J Med 2007;120:643. 39. Stone JH. Limited versus severe Wegener's granulomatosis: baseline data on patients în the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003;48:2299-309. 40. Guillevin L, Jarrousse B, Lok C, Lhote F, Jais JP, Le Thi Huong Du D, et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
B, Lok C, Lhote F, Jais JP, Le Thi Huong Du D, et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991;18:567-74. 41. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse în Wegener's granulomatosis. J Rheumatol 2003;30:80-8
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse în Wegener's granulomatosis. J Rheumatol 2003;30:80-8. 42. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44. 43. Aasarod K, Bostad L, Hammerstrom J, Jorstad S, Iversen BM. Renal histopathology and clinical course în 94 patients with Wegener's granulomatosis
EUR-Lex () [Corola-website/Law/227535_a_228864]
-
Hammerstrom J, Jorstad S, Iversen BM. Renal histopathology and clinical course în 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant 2001;16:953-60. 44. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide în the treatment of systemic vasculitis. QJM 1997;90:401-9. 45. Rihova Z, Jancova E, Merta M, Zabka J, Rysava R, Bartunkova J, et al. Daily oral versus pulse intravenous cyclophosphamide în the
EUR-Lex () [Corola-website/Law/227535_a_228864]